NPS down but claims PhIII cancer cases in short bowel drug trial are "not a signal"
This article was originally published in Scrip
Executive Summary
Investors on 31 October had to deal with both good news and not-so-good news regarding NPS Pharmaceuticals' interim data from a Phase III follow-on trial (STEP 2) with Gattex (teduglutide), its investigational agent for short bowel syndrome (SBS). On the one hand there was promising efficacy data, but on the other hand there were three cancer cases (two lung, one GI) in the trial.